Viral 'fitness' explains various AIDS drugs resistance
'fitness' of the HIV virus as a primary factor in explaining
different resistant patterns to the drugs that treat the disease.
The pioneering research may help to explain why some HIV medications lead to the development of drug-resistant HIV when patients take as few as two per cent of their medications while for other medications, resistance occurs only when patients take most of their pills.
Viral "fitness" refers to the virus' ability to replicate and cause disease. Incomplete pill-taking by patients causes HIV to mutate and become resistant to the effects of the medications, while the medications that were consumed, in turn, cause the newly resistant virus to become less fit.
The research, led by David Bangsberg an AIDS specialist at the University of California, San Francisco, is reported in the January 9 issue of the journal AIDS. The results could well point to alternative mechanisms of drug action or lead to different patterns of taking medications avoiding resistance.
Current therapies include either one NNRTI or protease inhibitor (non-boosted or boosted with a small amount of another potent PI) and two different antiretrovirals from the nucleoside reverse transcriptase inhibitor class.
Both NNRTIs and non-boosted protease inhibitors are potent antiretroviral drugs (ARVs) with demonstrated effectiveness in suppressing the HIV virus when taken in combination with other ARVs at high levels of pill taking as directed.
Researchers found that the type of medication is also a major factor. Differences in viral fitness of mutated resistant virus occur between different classes of antiretroviral drugs.
They also found that patients, who succeeded in completely suppressing HIV, had to take all or almost all of their medications as directed, resistant strains either do not occur or are suppressed.
"A non-nucleoside reverse transcriptase inhibitor (NNRTI), for example, can be taken one time by a pregnant woman to prevent mother-to-child transmission, and NNRTI-resistant HIV virus can develop," Bangsberg commented.
Yet patients taking unboosted protease inhibitors (PI) do not experience the peak risk of PI-resistant HIV developing unless they are taking most of their PIs but fall just short of full viral suppression.
The researchers found that NNRTI-resistant virus has an advantage over sensitive virus even at very low levels of adherence.
This happens because only a single mutation is required to create high-level NNRTI resistance and these mutations have little impact on the virus's ability to replicate.
PI-resistant virus, in contrast, requires multiple mutations, each of which significantly weakens the ability of the virus to replicate.
These PI-resistant viruses only emerge, therefore, when challenged with high concentrations of drug.
Overall, study findings showed that NNRTI resistance was found less often than PI resistance among patients who took the pills as directed.
"We believe that when new drug classes are developed, more attention should be given in defining how virologic fitness determines how different patterns of taking medications may lead to resistance," said Steven Deeks, associate professor of medicine at UCSF's Positive Health Program at SFGHMC and senior author on the study.
